Vutiglabridin is under clinical development by Glaceum and currently in Phase I for Age Related Macular Degeneration. According to GlobalData, Phase I drugs for Age Related Macular Degeneration have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vutiglabridin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vutiglabridin overview

HSG-4112 is under development for the treatment of obesity, overweight , Type 2 Diabetes Mellitus (T2DM), age related macular degeneration, non-alcoholic steatohepatitis (NASH), Parkinson’s disease and unspecified indication. The drug candidate is a first-in class hydrophobic isoflavonoid molecule administered through oral route in form of tablet. The drug candidate is a new chemical entity.

For a complete picture of Vutiglabridin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.